Inclusion Criteria
Patients must have:
- Asymptomatic or minimally symptomatic HIV infection (no evidence of AIDS).
- CD4 count <= 400 cells/mm3 within 6 weeks prior to study entry (CD4 count changed to 100 - 400 cells/mm3 per amendment).
- Tolerated the current nucleoside analog antiretroviral treatment for at least 4 weeks prior to study entry.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Known hypersensitivity to thymopentin or any component of the formulation.
- Significant chronic underlying medical illness that would impede study participation.
- Grade 2 or higher peripheral neuropathy related to nucleoside analog antiretroviral treatment.
Concurrent Medication:
Excluded:
- Any antiretroviral agents other than zidovudine, didanosine, or dideoxycytidine.
- HIV vaccines or any investigational or non-FDA approved medication or immunomodulatory or experimental therapy within 30 days prior to study entry.
Patients with the following prior condition are excluded:
Abnormal chest x-ray consistent with active opportunistic infection within 6 weeks prior to study entry.
Prior Medication:
Excluded:
- Any prior antiretroviral agents other than zidovudine, didanosine, or dideoxycytidine within 30 days prior to study entry.
Required:
- Current nucleoside analog antiretroviral treatment.
Required:
- Nucleoside analog antiretroviral treatment for at least 4 weeks prior to study entry.
Significant active alcohol or drug abuse sufficient to prevent study compliance.
Purpose
